Well, as much as I thought my routine would return to normal next week, we learned the schools are not going to open until September 6th at the earliest meaning.
The sector is doing well on the consummation of the long courtship of MDVN. I will be back with my commentary this week but am still not quite back to.
We now seem to be stuck in a small rut with the near term trend being slightly negative and nothing really to break it. Perhaps value investors step in at.
We certainly have seen some recent under-performance by the sector but given recent strength and run of bad news (trial failures, secondaries, and so on) this is not stunning. So.
The sector seems to be struggling a little but it would not be stunning to see some underperformance and consolidation after the recent run. We continue to get earnings headlines.
I was not going to write today but snuck into office with my kids in tow for a quick note on BMY. 1. This was a major surprise and critically.
It is more of the same but we had a nice late day rumor yesterday that triggered a reversal higher. Outside of that rumor not much in the way of.
Biotech is hot again. I know I may have just jinxed us but the sector continues to power higher even as the broader market spins its wheels. Obviously there will.
It is a mixed bag today in terms of stock reactions but the actual numbers continue to be good. I am not exactly sure why some stocks are reacting better.
We got a double barrel of bad news after the close last night but I must say the overall sector reaction is good. I have said this before but it.
Not a lot of additional news today. The sector continues to modestly outperform the broad market, which is good. The XBI crossed over the 200 day moving average (and actually.
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.***.
More of the same yesterday and still not a ton of news for this morning. The market is overbought even if the sector is still not anywhere near over bought.
There is nothing new in the market or the sector, so I suspect we see more of the same. The sector continues to track the broader market but is clearly.
The market continued its strength (even if we dipped red for a second today). If you remember in the lead up to the BREXT vote the cash balance sheets for.
Through many years, Achillion focused on HCV, among the biggest prizes in drug discovery. The problem is they entered the field late while working on a very popular target. A nearly.
The market and sector continue to do well. At least in terms of the macro market, we are back in the pattern where the most likely path of a market.
Yesterday was not a disaster but it was some kind of underperformance. Even as we got essentially a buyers panic at the end of the day, it still left many.